Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15742968 | 0.85 | USP2 (0.45) | USP2SMN1; SMN2HPGDEPHX2CYP4F2 | |
| SCHEMBL2943334 | 0.85 | USP2 (0.47) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL15076622 | 0.84 | USP2 (0.44) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL17447773 | 0.84 | USP2 (0.44) | USP2SMN1; SMN2HPGDEPHX2CTSK | |
| SCHEMBL17861638 | 0.82 | USP2 (0.45) | USP2SMN1; SMN2PDE4APDE4BPDE4C | |
| SCHEMBL597478 | 0.82 | GPR4 (0.46) | USP2SMN1; SMN2PDE4APDE4BPDE4C | |
| SCHEMBL7134674 | 0.82 | USP2 (0.40) | USP2SMN1; SMN2HPGDEPHX2CYP4F2 | |
| SCHEMBL6896206 | 0.82 | USP2 (0.47) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL19156954 | 0.82 | USP2 (0.47) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL15740834 | 0.82 | USP2 (0.42) | USP2SMN1; SMN2HPGDEPHX2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004014-A1 | Fungicides, microbiocides; glucanase inhibitor; prophylaxis, therapy for pneumocystis infections in humans, animals | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| WO-2004113368-A1 | CYCLIC LIPOPEPTIDES | ASTELLAS PHARMA INC. (JP) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004014-A1 | Fungicides, microbiocides; glucanase inhibitor; prophylaxis, therapy for pneumocystis infections in humans, animals | MAN2B1, MAN2A1, MANBA | USP2 4279/4885SMN1; SMN2 4495/4885PDE4A 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.